查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370932

植入前基因檢測市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按程序、產品、技術、按應用、最終用途行業、地區、競爭細分

Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Procedure By Product, By Technology, By Application, By End-Use Industry, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球植入前基因檢測（PGT）市場估值達到5.5728億美元，預計在預測期內將大幅成長，預計年複合成長率（CAGR）為8.22%，預計將達到8.9047億美元至2028年。

介紹：

植入前基因檢測是輔助生殖技術 (ART) 領域內使用的醫療程序，用於在胚胎植入子宮之前篩選胚胎是否有遺傳異常。此程序主要用於體外受精 (IVF) 治療期間，以提高成功懷孕的機會，同時最大限度地降低將某些遺傳性疾病遺傳給孩子的風險。植入前基因檢測有兩種主要類型：

市場概況
預測期 2024-2028
2022 年市場規模 5.5728億美元
2028 年市場規模 8.9047億美元
2023-2028 年年複合成長率 8.22%
成長最快的細分市場 植入前遺傳學診斷PGD部分
最大的市場 歐洲

1. 植入前非整倍體基因檢測 (PGT-A)：此檢測類型旨在篩選胚胎的染色體數量異常，特別是非整倍體。當胚胎具有異常數量的染色體時，就會發生非整倍性，可能導致流產或唐氏症等出生缺陷。 PGT-A 有助於識別具有正確染色體數量的胚胎，增加成功懷孕的可能性。

2. 單基因疾病植入前基因檢測 (PGT-M)：PGT-M 用於檢測已知存在於家族病史中的特定基因突變或疾病。當父母一方或雙方攜帶已知的基因突變，可能導致其後代出現嚴重的健康狀況（例如囊性纖維化或亨廷頓舞蹈症）時，就會使用該藥物。 PGT-M 允許選擇不攜帶基因突變的胚胎。

主要市場促進因素：

1. 遺傳性疾病發生率上升：

遺傳性疾病發生率的增加是全球植入前基因檢測（PGT）市場成長的重要動力。有遺傳性疾病家族史或攜帶特定基因突變的夫妻擴大轉向PGT，以降低將這些疾病遺傳給孩子的風險。 PGT 為他們提供了一種在植入前識別未受影響的胚胎的方法，從而增加了擁有健康後代的機會。 PGT 在早期發育階段對胚胎進行全面的遺傳篩檢，檢測多種遺傳異常，包括單基因疾病和染色體非整倍體。人們對遺傳性疾病的認知不斷提高，加上先進醫療技術的出現，使得更多的個人和夫妻主動尋求解決方案來減輕這些風險。

2. 基因篩檢技術的進步：

基因篩檢技術的進步極大地促進了全球植入前基因檢測（PGT）市場的成長。這些技術創新提高了 PGT 程序的準確性、效率和可及性，使其對更廣泛的個人和夫婦更具吸引力和可行性。先進的基因篩檢技術在檢測胚胎基因異常和突變方面提供了更高的準確性和可靠性，減少了假陽性和假陰性結果。更新的技術可以對胚胎進行全面的遺傳分析，從而可以同時篩檢多種遺傳性疾病和染色體異常。這些創新也促進了用於胚胎評估的非侵入性或微創技術的發展，使得該過程壓力更小並且可能更安全。自動化和高通量篩選技術簡化了 PGT 流程，使診所能夠有效處理大量樣本。

3. IVF（體外受精）需求不斷成長：

對 IVF 手術的需求不斷成長，大大推動了全球植入前基因檢測 (PGT) 市場的成長。 IVF 和 PGT 通常會結合使用，以提高生育治療的成功率並確保更健康的懷孕。 PGT 通常與 IVF 一起使用，以在植入前評估胚胎的遺傳健康狀況。隨著 IVF 需求的增加，越來越多的個人和夫妻可以選擇將 IVF 與 PGT 相結合，從而提高 PGT 服務的採用率。 IVF 與 PGT 的結合使醫療保健提供者能夠選擇遺傳異常風險較低的胚胎進行植入，從而增加成功懷孕和活產的機會。

主要市場挑戰：

1. 倫理和道德問題：

使用 PGT 來選擇特定特徵（例如眼睛顏色或智力）會引發倫理擔憂，即對沒有這些特徵的個體可能會歧視。它可能導致基於基因組成的社會分裂。此外，PGT 用於篩檢遺傳疾病可能會引發有關墮胎的道德問題，因為有些人認為墮胎在道德上是錯誤的，而另一些人則認為在嚴重遺傳疾病的情況下墮胎是合理的。

2. 不準確和誤報/誤報：

PGT 的不準確可能會導致選擇患有遺傳疾病的胚胎或丟棄健康的胚胎，從而影響成功懷孕的機會。假陽性和假陰性可能會對接受 PGT 的患者產生嚴重後果，這凸顯了對高精度檢測方法的需求。

3. 訪問和意識有限：

PGT 相對較新，其可用性因地區而異。對於某些個人或夫婦來說，獲得 PGT 服務的機會有限，尤其是在農村地區，可能會成為障礙。此外，許多人不了解 PGT 及其好處，這可能會影響他們對其使用做出明智決定的能力。

主要市場趨勢：

1. 越來越多的生育診所提供 PGT 服務：

全球植入前基因檢測市場見證了越來越多的生育診所提供 PGT 服務。這一趨勢使得更多人群更容易接受 PGT 程序，使個人和夫婦能夠進行基因檢測並就計劃生育做出明智的決定。它還促進了生育診所之間的競爭，有可能提高服務品質、技術產品和定價。

細分洞見：

程式見解：

2022年，植入前基因檢測市場主要由植入前基因診斷（PGD）主導，而這一趨勢預計將持續下去。 PGD​​ 用於在植入前識別胚胎中的特定遺傳缺陷或染色體異常。它通常由攜帶遺傳性疾病並希望防止這些疾病遺傳給後代的夫婦使用。

產品見解：

2022年，植入前基因檢測市場主要由試藥和耗材領域主導，而這種主導地位預計將持續下去。試劑和耗材是進行 PGT 程序的重要組成部分，包括準確有效測試所需的各種產品。

技術見解：

2022年，植入前基因檢測市場主要由聚合酶鍊式反應（PCR）領域主導，而這一趨勢預計將持續下去。 PCR 因其在擴增特定 DNA 序列方面的高精度和靈敏度而受到廣泛認可，非常適合 PGT 中的精確遺傳分析。

應用見解：

2022年，植入前基因檢測市場主要以非整倍體篩檢為主，預計將持續成長。非整倍體篩檢可幫助生育診所選擇染色體含量正確的胚胎，增加成功植入的機會並降低流產風險。

最終用途產業見解：

2022年，植入前基因檢測市場主要由醫院領域主導，預計這一趨勢將持續下去。醫院吸引了大量尋求生育治療的患者，許多醫院提供全面的生殖服務，包括 PGT。醫院進行的先進技術和研究有助於提高檢測率。

區域見解：

歐洲地區已成為全球植入前基因檢測市場的領導者。歐洲發達的醫療保健系統、先進的醫療設施以及輔助生殖技術和基因檢測的監管框架有助於該地區在 PGT 採用方面的突出地位。由於延遲生育和對遺傳性疾病認知的提高等因素的推動，該地區對生育治療的需求也很大。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球植入前基因檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依程序（植入前遺傳診斷（PGD）、植入前基因篩檢（PGS））
    • 按產品（試劑及耗材、儀器、軟體）
    • 依技術（次世代定序、聚合酶鍊式反應、螢光原位雜合技術等）
    • 按應用（染色體異常、X連鎖疾病、胚胎檢測、HLA分型、其他）
    • 依最終用途產業（生育中心、醫院、診斷中心、研究中心和學術實驗室）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美植入前基因檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按程式
    • 按產品分類
    • 按應用
    • 按最終用途行業
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲植入前基因檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按程式
    • 按產品分類
    • 按應用
    • 按最終用途行業
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區植入前基因檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按程式
    • 按產品分類
    • 按應用
    • 按最終用途行業
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲植入前基因檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按程式
    • 按產品分類
    • 按應用
    • 按最終用途行業
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲植入前基因檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按程式
    • 按產品分類
    • 按應用
    • 按最終用途行業
    • 按國家/地區
  • MEA：國家分析
    • 南非植入前基因檢測
    • 沙烏地阿拉伯植入前基因檢測
    • 阿拉伯聯合大公國植入前基因檢測

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • California Pacific Medical Center (CPMC)
    • CombiMatrix
    • CooperSurgical, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genea Limited
    • Genesis Genetics
    • Good Start Genetics, Inc.
    • IGENOMIX
    • Illumina, Inc.
    • Invitae Corporation
    • Laboratory Corporation of America Holdings

第 16 章：策略建議

簡介目錄
Product Code: 13099

The Global Preimplantation Genetic Testing (PGT) Market reached a valuation of USD 557.28 Million in 2022 and is expected to experience substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 8.22% and expected to reach USD 890.47 Million through 2028.

Introduction:

Preimplantation Genetic Testing is a medical procedure utilized within the realm of assisted reproductive technology (ART) to screen embryos for genetic abnormalities before their implantation into the uterus. This procedure is primarily employed during in vitro fertilization (IVF) treatments to enhance the chances of a successful pregnancy while minimizing the risk of passing certain genetic disorders to the child. There are two primary types of preimplantation genetic testing:

Market Overview
Forecast Period2024-2028
Market Size 2022USD 557.28 Million
Market Size 2028USD 890.47 Million
CAGR 2023-20288.22%
Fastest Growing SegmentPre-implantation genetic diagnosis PGD segment
Largest MarketEurope

1. Preimplantation Genetic Testing for Aneuploidy (PGT-A): This testing type is designed to screen embryos for numerical chromosomal abnormalities, particularly aneuploidies. Aneuploidy occurs when an embryo has an abnormal number of chromosomes, potentially leading to miscarriages or birth defects like Down syndrome. PGT-A helps identify embryos with the correct number of chromosomes, increasing the likelihood of a successful pregnancy.

2. Preimplantation Genetic Testing for Monogenic Disorders (PGT-M): PGT-M is employed to detect specific genetic mutations or disorders known to be present in a family's medical history. It is used when one or both parents carry a known genetic mutation that could lead to severe health conditions in their offspring, such as cystic fibrosis or Huntington's disease. PGT-M allows for the selection of embryos that do not carry the genetic mutation.

Key Market Drivers:

1. Rising Incidence of Genetic Disorders:

The increasing occurrence of genetic disorders is a significant driver for the growth of the global Preimplantation Genetic Testing (PGT) market. Couples with a family history of genetic disorders or those carrying specific genetic mutations are increasingly turning to PGT to reduce the risk of passing these disorders on to their children. PGT offers them a way to identify unaffected embryos before implantation, increasing the chances of having healthy offspring. PGT provides comprehensive genetic screening of embryos at an early developmental stage, detecting a wide range of genetic abnormalities, including single gene disorders and chromosomal aneuploidies. The rising awareness of genetic disorders and the availability of advanced medical technologies have made more individuals and couples proactive in seeking solutions to mitigate these risks.

2. Advancements in Genetic Screening Technologies:

Advancements in genetic screening technologies significantly contribute to the growth of the global Preimplantation Genetic Testing (PGT) market. These technological innovations enhance the accuracy, efficiency, and accessibility of PGT procedures, making them more attractive and feasible for a broader range of individuals and couples. Advanced genetic screening technologies offer higher accuracy and reliability in detecting genetic abnormalities and mutations in embryos, reducing false-positive and false-negative results. Newer technologies enable comprehensive genetic analysis of embryos, allowing for simultaneous screening of multiple genetic disorders and chromosomal abnormalities. These innovations also lead to the development of non-invasive or minimally invasive techniques for embryo assessment, making the procedure less stressful and potentially safer. Automation and high-throughput screening technologies streamline the PGT process, allowing clinics to handle larger volumes of samples efficiently.

3. Rising Demand for IVF (In Vitro Fertilization):

The increasing demand for IVF procedures significantly drives the growth of the global Preimplantation Genetic Testing (PGT) market. IVF and PGT are often combined to enhance the success rates of fertility treatments and ensure healthier pregnancies. PGT is commonly used alongside IVF to assess the genetic health of embryos before implantation. As the demand for IVF rises, more individuals and couples are exposed to the option of combining IVF with PGT, leading to higher adoption rates of PGT services. The combination of IVF with PGT allows healthcare providers to select embryos with a lower risk of genetic abnormalities for implantation, increasing the chances of successful pregnancies and live births.

Key Market Challenges:

1. Ethical and Moral Concerns:

The use of PGT to select for specific traits, such as eye color or intelligence, raises ethical concerns about potential discrimination against individuals without those traits. It could lead to societal divisions based on genetic makeup. Additionally, PGT's application to screen for genetic diseases may raise moral questions about abortion, as some individuals believe it is morally wrong, while others justify it in cases of serious genetic diseases.

2. Inaccuracies and False Positives/Negatives:

Inaccuracies in PGT can lead to the selection of embryos with genetic diseases or the discarding of healthy embryos, affecting the chances of a successful pregnancy. False positives and false negatives can have significant consequences for patients undergoing PGT, emphasizing the need for highly accurate testing methods.

3. Limited Access and Awareness:

PGT is relatively new, and its availability varies by region. Limited access to PGT services, especially in rural areas, can be a barrier for some individuals or couples. Additionally, many people are not aware of PGT and its benefits, which can impact their ability to make informed decisions about its use.

Key Market Trends:

1. Growing Number of Fertility Clinics Offering PGT Services:

The global Preimplantation Genetic Testing market is witnessing a growing number of fertility clinics offering PGT services. This trend makes PGT procedures more accessible to a larger population, allowing individuals and couples to access genetic testing and make informed decisions about family planning. It also fosters competition among fertility clinics, potentially leading to improvements in service quality, technology offerings, and pricing.

Segmental Insights:

Procedure Insights:

In 2022, the Preimplantation Genetic Testing market was predominantly dominated by Pre-implantation genetic diagnosis (PGD), and this trend is expected to continue. PGD is used to identify specific genetic defects or chromosomal abnormalities in embryos before implantation. It is commonly employed by couples who are carriers of genetic disorders and want to prevent the transmission of these conditions to their offspring.

Product Insights:

In 2022, the Preimplantation Genetic Testing market was primarily dominated by the reagents and consumables segment, and this dominance is expected to persist. Reagents and consumables are essential components for conducting PGT procedures, encompassing various products required for accurate and effective testing.

Technology Insights:

In 2022, the Preimplantation Genetic Testing market was mainly dominated by the polymerase chain reaction (PCR) segment, and this trend is expected to continue. PCR is widely recognized for its high accuracy and sensitivity in amplifying specific DNA sequences, making it well-suited for precise genetic analysis in PGT.

Application Insights:

In 2022, the Preimplantation Genetic Testing market was primarily dominated by aneuploidy screening, which is expected to continue its growth. Aneuploidy screening helps fertility clinics select embryos with the correct chromosomal content, increasing the chances of successful implantation and reducing the risk of miscarriages.

End-Use Industry Insights:

In 2022, the Preimplantation Genetic Testing market was mainly dominated by the hospital segment, and this trend is expected to continue. Hospitals attract a high volume of patients seeking fertility treatments, and many offer comprehensive reproductive services, including PGT. Advanced technology and research conducted in hospitals contribute to higher testing rates.

Regional Insights:

The Europe region has established itself as the leader in the global Preimplantation Genetic Testing Market. Europe's well-developed healthcare systems, advanced medical facilities, and regulatory frameworks governing assisted reproductive technologies and genetic testing contribute to the region's prominence in PGT adoption. The region also exhibits a substantial demand for fertility treatments, driven by factors such as delayed parenthood and increased awareness of genetic disorders.

Key Market Players

  • California Pacific Medical Center (CPMC)
  • CombiMatrix Corp
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genea Limited
  • Genesis Genetics
  • Good Start Genetics, Inc.
  • IGENOMIX
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings

Report Scope:

In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preimplantation Genetic Testing Market, By Procedure:

  • Pre-implantation genetic diagnosis (PDS)
  • Preimplantation Genetic Screening (PGS)

Preimplantation Genetic Testing Market, By Product:

  • Reagents and Consumables
  • Instruments
  • Software

Preimplantation Genetic Testing Market, By Technology:

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)
  • Others

Preimplantation Genetic Testing Market, By Application:

  • Chromosomal Abnormalities
  • X-linked Diseases
  • Embryo Testing
  • Aneuploidy Screening
  • HLA Typing
  • Other Applications

Global Preimplantation Genetic Testing Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Preimplantation Genetic Testing Market.

Available Customizations:

  • Global Preimplantation Genetic Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preimplantation Genetic Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Procedure (Pre-implantation genetic diagnosis (PGD), preimplantation genetic screening (PGS))
    • 5.2.2. By Product (Reagents and Consumables, Instruments, Software)
    • 5.2.3. By Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Site Hybridization, Others)
    • 5.2.4. By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, HLA Typing, Others)
    • 5.2.5. By End-Use Industry (Fertility Centres, Hospitals, Diagnostics Centres, Research Centres And Academic Labs)
    • 5.2.6. By Company (2022)
    • 5.2.7. By Region
  • 5.3. Market Map

6. North America Preimplantation Genetic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Procedure
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End-Use Industry
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preimplantation Genetic Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Procedure
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-Use Industry
    • 6.3.2. Mexico Preimplantation Genetic Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Procedure
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-Use Industry
    • 6.3.3. Canada Preimplantation Genetic Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Procedure
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-Use Industry

7. Europe Preimplantation Genetic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Procedure
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End-Use Industry
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Preimplantation Genetic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Procedure
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-Use Industry
    • 7.3.2. Germany Preimplantation Genetic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Procedure
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-Use Industry
    • 7.3.3. United Kingdom Preimplantation Genetic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Procedure
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-Use Industry
    • 7.3.4. Italy Preimplantation Genetic Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Procedure
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-Use Industry
    • 7.3.5. Spain Preimplantation Genetic Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Procedure
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-Use Industry

8. Asia-Pacific Preimplantation Genetic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Procedure
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End-Use Industry
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Preimplantation Genetic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Procedure
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-Use Industry
    • 8.3.2. India Preimplantation Genetic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Procedure
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-Use Industry
    • 8.3.3. South Korea Preimplantation Genetic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Procedure
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-Use Industry
    • 8.3.4. Japan Preimplantation Genetic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Procedure
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-Use Industry
    • 8.3.5. Australia Preimplantation Genetic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Procedure
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-Use Industry

9. South America Preimplantation Genetic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Procedure
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End-Use Industry
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Preimplantation Genetic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Procedure
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-Use Industry
    • 9.3.2. Argentina Preimplantation Genetic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Procedure
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-Use Industry
    • 9.3.3. Colombia Preimplantation Genetic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Procedure
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-Use Industry

10. Middle East and Africa Preimplantation Genetic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Procedure
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End-Use Industry
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Preimplantation Genetic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Procedure
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-Use Industry
    • 10.3.2. Saudi Arabia Preimplantation Genetic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Procedure
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-Use Industry
    • 10.3.3. UAE Preimplantation Genetic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Procedure
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. California Pacific Medical Center (CPMC)
    • 15.6.2. CombiMatrix
    • 15.6.3. CooperSurgical, Inc.
    • 15.6.4. F. Hoffmann-La Roche Ltd.
    • 15.6.5. Genea Limited
    • 15.6.6. Genesis Genetics
    • 15.6.7. Good Start Genetics, Inc.
    • 15.6.8. IGENOMIX
    • 15.6.9. Illumina, Inc.
    • 15.6.10. Invitae Corporation
    • 15.6.11. Laboratory Corporation of America Holdings

16. Strategic Recommendations